Cargando…
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
BACKGROUND: Patients with heart failure with preserved ejection fraction have significant impairment in health-related quality of life. In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction), we evaluated the efficacy of e...
Autores principales: | Butler, Javed, Filippatos, Gerasimos, Jamal Siddiqi, Tariq, Brueckmann, Martina, Böhm, Michael, Chopra, Vijay K., Pedro Ferreira, João, Januzzi, James L., Kaul, Sanjay, Piña, Ileana L., Ponikowski, Piotr, Shah, Sanjiv J., Senni, Michele, Vedin, Ola, Verma, Subodh, Peil, Barbara, Pocock, Stuart J., Zannad, Faiez, Packer, Milton, Anker, Stefan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763045/ https://www.ncbi.nlm.nih.gov/pubmed/34779658 http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057812 |
Ejemplares similares
-
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
por: Packer, Milton, et al.
Publicado: (2021) -
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2023) -
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022) -
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022) -
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)